Contraline
Charlottesville, US · Founded 2017 · Delaware corporation · 21 known investors
Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception. The company works on translational reproductive biology research to bring new contraceptive options to market.
BiotechDigital HealthMedical Devices
Founders & leadership
Contraline was founded in 2017 by Kevin S Eisenfrats, Kevin Eisenfrats, and John Herr.
KS
Kevin S EisenfratsCo-founder
KE
Kevin EisenfratsCo-Founder and CEO
JH
John HerrCo-Founder
Board
IV
Iris Van Alderwerelt van RosenburghBoard director
GB
MJ
Martin J EmersonBoard director
TT
Tom ThorpeBoard director
MK
Michael KingBoard director
Investors · 21
Biotechnology Value Fund✓ verifiedSan Francisco
MBX Capital✓ verifiedClaymont · $250K – $2.5Mvia Gurdane Bhutani · board
Allied Venture PartnersCalgary · $100K – $350K
Amboy Street VenturesVenice
Aurum Venture PartnersPleasanton
Beni Venture CapitalMiami · $100K – $250K
Cleo CapitalNew York · $100K – $1M
Evolution VC PartnersNew York
Foreground CapitalBoston
Graphene VenturesPalo Alto · $500K – $2M
Helium-3 VenturesNew York
JourneyOne VenturesBouldervia Helene Servillon · inferred
Kima VenturesParis · $50K – $5M
Lumira VenturesToronto · $1M – $10M
MetaplanetTallinn · $500K – $10M
Myelin VCMontevideo · $250K – $1M
ShangBay Capital LLCPalo Alto
Strawberry Creek VenturesManchester
VU Venture PartnersSan Francisco · $200K – $1M
GV (Google Ventures)reported · 2 sourcesMountain View · $250K – $50M
RA CapitalreportedBostonvia Laura Stoppel · quoted
Reported raises · per SEC filings
Form D private placements$63M disclosed across 2 rounds · 2021–2026
▶$55.8MraisedJun 2026 · 77 investors · BiotechnologyRule 506(b)
▶$55.8MraisedJun 2026 · 77 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin S EisenfratsExecutive Officer, Director, Promoter
- Iris Van Alderwerelt van RosenburghDirector
- Martin J EmersonDirector
- Gurdane BhutaniDirector
- Offering amount
- $115.9M
- Amount sold
- $55.8M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.2MraisedApr 2022 · 22 investors · BiotechnologyRule 506(b)
▶$7.2MraisedApr 2022 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Martin EmersonDirector
- Gurdane BhutaniDirector
- Tom ThorpeDirector
- Michael KingDirector
- Kevin EisenfratsExecutive Officer, Director, Promoter
- Offering amount
- $7.5M
- Amount sold
- $7.2M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapRead on Scientific American271 shared keywordsScientific American is a science and technology news publication covering research, discoveries, and developments across fields such as astronomy, biology, physics, health, and climate. It publishes articles, magazine issues, discussions, and organizes reader travel experiences and editorial features.
Nbcnews241 shared keywordsNBC News is a news organization that publishes reporting and analysis on U.S. politics, national events, and current affairs for a general audience.
Companies competing with Contraline for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series Bfiercebiotech.com · Aug 2026
Contraline has filed a notice of an exempt offering of securities to raise $115,929,658.00 in New Funding. - intelligence360intelligence360.news · Jul 2026
Contraline Secures $92.5M to Push Its Male Birth Control Candidates Forward - MedCity Newsmedcitynews.com · Jun 2026
Contraline Closes $92.5M Series B for Male Contraceptiveallsci.com · Jun 2026Frequently asked questions
- What does Contraline do?
- Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception. The company works on translational reproductive biology research to bring new contraceptive options to market.
- Who founded Contraline?
- Contraline was founded by Kevin S Eisenfrats, Kevin Eisenfrats, John Herr in 2017.
- Who are Contraline's investors?
- Contraline's investors include Biotechnology Value Fund, MBX Capital, Allied Venture Partners, Amboy Street Ventures, Aurum Venture Partners, Beni Venture Capital, Cleo Capital, Evolution VC Partners and 13 more.
- How much funding has Contraline raised?
- Contraline has disclosed $63M raised across 2 rounds.
- Where is Contraline headquartered?
- Contraline is headquartered in Charlottesville, US.